May 17, 2020

How Canada's Tilray is boosting the medical marijuana industry in Australia

Tilray
Medicinal marijuana
Canada
Australia
Admin
2 min
How Canada's Tilray is boosting the medical marijuana industry in Australia
In an effort to provide groundbreaking research for a treatment of nausea and vomiting during chemotherapy, Canadian medical cannabis research and produ...

In an effort to provide groundbreaking research for a treatment of nausea and vomiting during chemotherapy, Canadian medical cannabis research and production company Tilray has teamed up with the NSW Government and the University of Sydney.

The partnership will create the largest clinical trial of marijuana’s affect on chemotherapy patients in the world. Tilray’s ultimate plan is to import cannabis products from its state-of-the-art Vancouver Island facility that has helped bring the global $250 billion industry to Australia.

RELATED TOPIC: Is marijuana the best remedy for PMS? Foria Relief says yes

“We are very excited and optimistic about this partnership with Tilray,” said University of Sydney associate professor Peter Grimison. “We believe Tilray is well positioned to develop appropriate medical products from cannabis.

“We envision additional future trials with products that they develop for other indications as well.”

RELATED TOPIC: Australian economy looks for lift from medical marijuana

It’s believed by many that the growing medicinal marijuana industry will create thousands of skilled jobs while generating millions of dollars in foreign investment.

The trial is scheduled to begin as early as this summer once regulatory approval and import permits are granted, and will be held at Chris O’Brien Lifehouse in Sydney as well as other sites in NSW. It will be conducted by an interdisciplinary group of researchers who specialise in cannabinoids and oncology.

RELATED TOPIC: Health Canada attacks marijuana advertising—Is the industry going up in smoke?

The purpose of the trial is to examine the safety and tolerability of a novel cannabis-derived study drug in patients undergoing chemotherapy.

“Tilray is at the forefront of clinical research in the medical cannabis field,” said Tilray director of clinical research Dr. Catherine Jacobson. “We are providing physicians and researchers with cannabis-derived study drugs that meet regulatory standards for human trials and which are based on studies indicating a high likelihood of success in treating specific diseases and disease-related symptoms.”

Let's connect!   

Click here to read the latest edition of Healthcare Global magazine!

Share article

Jun 22, 2021

Bachem turns 50 - a timeline

pharma
supplychain
peptides
medication
3 min
As Bachem turns 50, we take a look at the company's history

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.  

1971 - beginnings

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes. 

1977 - 1981 - early growth

Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150. 

 1987 - 1996 - worldwide expansion

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988. 

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance. 

 1998 - 2003 - Bachem goes public

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and  Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients.  By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day. 

2007 - 2013 - acquisitions

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services. 

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion. 

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas. 

2016 - 2019 - a global leader

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K. 

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future. 

2020 - COVID-19

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and  272 new employees are hired.  

2021 - a milestone anniversary

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it  remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are  plans to continue expanding. 

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Share article